Mode
Text Size
Log in / Sign up
N/A Completed N=321 Treatment

S-ICD® System IDE Clinical Study

Tachycardia, Ventricular
Source: ClinicalTrials.gov NCT01064076 ↗
Enrolled (actual)
321
Serious AEs
16.2%
Results posted
Mar 2017
Primary outcomePrimary: Percentage of Participants Free of Type I Complications at 180 Days. — 99.0 percentage of participants

Summary

This clinical study is designed to evaluate the safety and effectiveness of the subcutaneous implantable defibrillator (S-ICD) System.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants Free of Type I Complications at 180 Days.
99.0
PRIMARY
Percentage of Participants Who Pass Induced VF Conversion Test
96.5

Eligibility Criteria

Inclusion Criteria

  • For patients without an existing transvenous device
  • Patient meets Class I, Class IIa or Class IIb indications/recommendations for ICD implantation per the current published guidelines at the time of enrollment
  • For patients with an existing transvenous device
  • Patient requires replacement or revision of an existing implanted transvenous ICD system
  • Age is ≥ 18 years
  • An appropriate pre-operative ECG per template provided

Exclusion Criteria

  • Any condition which precludes the subject's ability to comply with the study requirements, including completion of the study.
  • Females who are pregnant or lactating and pre-menopausal women who are unwilling to use adequate birth control for the duration of the study.
  • Participation in any other investigational study without prior written consent from the study sponsor.
  • Patients with a serious medical condition and life expectancy of less than one year.
  • Patients with documented spontaneous and frequently recurring VT that is reliably terminated with anti-tachycardia pacing, unless the patient is not a candidate for a transvenous ICD system.
  • Patients with existing epicardial patches or subcutaneous electrodes in the left thoracic quadrant.
  • Patients with unipolar pacemakers or implanted devices that revert to unipolar pacing.
  • Patients with severely impaired kidney function as measured by a Cockcroft-Gault Glomerular Filtration Rate (GFR) with an estimated GFR ≤ 29.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01064076). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search